Familial hypercholesterolaemia: A pressing issue for European health care

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 223-226

  Brice, Philippa ^a   Burton, Hilary ^a   Edwards, Christopher W ^b   Humphries, Steve E ^c   Aitman, Timothy J ^b  

^a PHG FOUNDATION   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cascade screening; DNA testing; Familial hypercholesterolaemia; Genetic diagnosis; Low density lipoprotein cholesterol (LDL cholesterol); Policy

Indexed keywords

EUROPE; EUROPEAN HEALTH CARE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; GENOME; HEALTH CARE; HUMAN; MORTALITY; NOTE; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SCREENING; UNITED KINGDOM;

CASCADE SCREENING; DNA TESTING; FAMILIAL HYPERCHOLESTEROLAEMIA; GENETIC DIAGNOSIS; LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-CHOLESTEROL); POLICY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; EUROPE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; GREAT BRITAIN; HEALTH POLICY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS;

EID: 84888100073     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.019     Document Type: Note

References (29)

1. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J August 2013, 15. [Epub ahead of print]. 10.1093/eurheartj/eht273.
2. Benn M., Watts G.F., Tybjaerg-Hansen A., et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. JClin Endocrinol Metab 2012, 97:3956-3964.
3. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223:262-268.
4. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969, 2:1380-1382.
5. Futema M., Plagnol V., Whittall R.A., et al. Use of targeted exome sequencing as a diagnostic tool for familial hypercholesterolaemia. JMed Genet 2012, 49(10):644-649.
6. Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007, 4(4):214-225.
7. Talmud P.J., Shah S., Whittall R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013, 381(9874):1293-1301.
8. Goldberg A.C. Novel therapies and new targets of treatment for familial hypercholesterolemia. JClin Lipidol 2010, 4(5):350-356.
9. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012, 126(20):2408-2417.
10. Neil A., Cooper J., Betteridge J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29(21):2625-2633.
11. Versmissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008, 337:a2423.
12. Wiegman A., De Groot E., Hutten B.A., et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004, 363(9406):369-370.
13. Braamskamp M.J.A.M., Wijburg F.A., Wiegman A. Drug therapy of hypercholesterolaemia in children and adolescents. Drugs 2012, 72(6):759-772.
14. Marks D., Thorogood M., Neil H.A.W., et al. Areview on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168:1-14.
15. National Institute for Health and Clinical Excellence Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia 2008, NICE, London, (Clinical guideline 71). Available from:, [accessed 28 August 2013]. http://www.nice.org.uk/CG71.
16. Damgaard D., Larsen M.L., Nissen P.H., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005, 180:155-160.
17. Starr B., Hadfield S.G., Hutten B.A., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008, 46(6):791-803.
18. Usifo E., Leigh S.E., Whittall R.A., et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012, 76(5):387-401.
19. Huijgen R., Hutten B.A., Kindt I., et al. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012, 5:354-359.
20. Mooney H. Families at risk of genetically high cholesterol are not being spotted, says royal college. BMJ 2011, 342:d520.
21. Nherera L., Marks D., Minhas R., et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011, 97:1175-1181.
22. National Institute for Health and Clinical Excellence Diagnostics guidance 2: elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia 2011, NICE, London, (Diagnostics Guidance 2). Available from:, [accessed 28 August 2013]. http://www.nice.org.uk/DG2.
23. Heart U.K. Saving lives, saving families the health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH) 2012, Available from:. http://www.heartuk.org.uk/files/uploads/documents/HUK_SavingLivesSavingFamilies_FHreport_Feb2012.pdf.
24. Hollants S., Redeker E.J.W., Matthijs G. Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes. Clin Chem 2012, 58(4):717-724.
25. Vandrovcova J., Thomas E.R., Atanur S.S., et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med 2013 May 16, [Epub ahead of print]. 10.1038/gim.2013.55.
26. Umans-Eckenhausen M.A., Defesche J.C., Sijbrands E.J., et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001, 357:165-168.
27. Prime Minister's Office, 10 Downing Street DNA tests to revolutionise fight against cancer and help 100,000 NHS patients 10 December 2012, Press release, Available from:, [accessed 28 August 2013]. http://www.gov.uk/government/news/dna-tests-to-revolutionise-fight-against-cancer-and-help-100000-nhs-patients.
28. Department of Health Cardiovascular Disease Outcomes Strategy Gateway reference 18747 05 March 2013, [Government report online], Available from:, [accessed 28 August 2013]. http://www.gov.uk/government/publications/improving-cardiovascular-disease-outcomes-strategy.
29. National Institute for Health and Clinical Excellence Familial hypercholesterolaemia 2013, NICE, London, (Quality Standards 41) Available from:, [accessed 28 August 2013]. http://www.nice.org.uk/QS41.